Thrombolytic therapy in patients with cerebral infarction can be effective immediately if the embolus can be dissolved. Thrombolytic therapy can rapidly restore cerebral blood flow, improve brain tissue metabolism, salvage only functionally altered semidark zone tissues around cerebral infarction, avoid the formation of necrosis, improve the signs and symptoms of neurological deficits to the maximum extent, and reduce the disability and mortality rate of patients. Thrombolytic therapy is mainly indicated for patients within 6 hours of onset, i.e., in the hyperacute phase. If the patient has an onset time of less than 4.5 hours, intravenous thrombolysis with alteplase is routinely given. If the time of onset is greater than 4.5 hours, thrombolysis with urokinase is routinely applied within 6 hours. Anti-platelet aggregation as well as anticoagulation are not routinely applied within 24 hours of thrombolysis in patients treated with thrombolysis. Anti-platelet aggregation and anticoagulation are mainly applied after 24 hours of thrombolysis in patients. The commonly used antiplatelet aggregation drugs include aspirin, or clopidogrel if aspirin is not tolerated, and anticoagulant drugs mainly include heparin and low molecular heparin.